Actual Use Trial of Naproxen Sodium (Kiefer AUT)
An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Hoover, Alabama, Forente stater, 35226
-
McCalla, Alabama, Forente stater, 35111-3406
-
Pinson, Alabama, Forente stater, 35126
-
-
Arizona
-
Mesa, Arizona, Forente stater, 85202
-
-
California
-
Anaheim, California, Forente stater, 92801
-
Oceanside, California, Forente stater, 92054
-
Yorba Linda, California, Forente stater, 92886
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66209
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21228
-
-
Minnesota
-
Andover, Minnesota, Forente stater, 55304
-
Elk River, Minnesota, Forente stater, 55330
-
Fridley, Minnesota, Forente stater, 55432
-
Northfield, Minnesota, Forente stater, 55057-2434
-
Rosemount, Minnesota, Forente stater, 55068
-
Roseville, Minnesota, Forente stater, 55113
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
-
Savannah, Missouri, Forente stater, 64485
-
St. Joseph, Missouri, Forente stater, 64504
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87104
-
Albuquerque, New Mexico, Forente stater, 87107
-
Taos, New Mexico, Forente stater, 87571
-
-
Utah
-
Bountiful, Utah, Forente stater, 84010
-
Hurricane, Utah, Forente stater, 84737
-
Layton, Utah, Forente stater, 84041
-
Ogden, Utah, Forente stater, 84401
-
Salt Lake City, Utah, Forente stater, 84121
-
Salt Lake City, Utah, Forente stater, 84102
-
Syracuse, Utah, Forente stater, 84075
-
West Jordan, Utah, Forente stater, 84088
-
-
Virginia
-
Montpelier, Virginia, Forente stater, 23192
-
Richmond, Virginia, Forente stater, 23221
-
-
Washington
-
Bellevue, Washington, Forente stater, 98007
-
Kenmore, Washington, Forente stater, 98028
-
Snohomish, Washington, Forente stater, 98290
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- At least 12 years of age
- Report taking OTC analgesics for pain on at least 5 days in the last month
- Report having had pain at least once in the last 3 months lasting longer than 12 hours or that they believe would have lasted longer than 12 hours if they had not treated it
- Able to read and understand English
- Provide written informed consent (subjects 12-17 years of age provide written assent and/or parent or legal guardian provide written consent)
- Provide contact information
- Purchase the investigational product
Exclusion Criteria:
- Have participated in a trial involving OTC analgesics in the last 6 months
- They or someone else in the household work for a market research company, an advertising agency, a public relations firm, a pharmaceutical company, as a healthcare professional, or as part of a health care practice (eliminated for reasons of confidentiality or increased awareness of drugs and their labels)
- Have a history of known allergies to NSAIDs (i.e., naproxen, ibuprofen, aspirin, etc.)
- Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
- (Female subjects) are pregnant or breastfeeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm 1
|
BAYH6689; oral tablet used as needed upon incidence of pain
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Estimated Percentage of Misuse for Non-Therapeutic Reasons
Tidsramme: 28 days
|
The primary objective of this trial was to determine the percentage of non-therapeutic misuse.
Two aspects of consumer use of Aleve 24 Hour were examined: the frequency at which consumers exceeded the label-defined daily dose modified by those who did so for non-therapeutic reasons.
|
28 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Non-therapeutic Reasons for Misuse
Tidsramme: 28 days
|
Those subjects in the Reasons for Misuse Cohort who did not state misuse due to need for additional pain relief were categorized to Non-therapeutic misuse.
|
28 days
|
|
Estimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course
Tidsramme: 28 days
|
This endpoint was an assessment of whether the rate of non-therapeutic misuse exceeded the pre-defined acceptable threshold for non-therapeutic misuse.
The difference lay in the estimation of misuse in the Patterns of Use Cohort by using 10-day treatment courses rather than by "use day".
A treatment course for each subject began on the first day they recorded taking one or more tablets which was followed by nine consecutive "evaluable days."
|
28 days
|
|
Percentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days
Tidsramme: 28 days
|
Percentage of participants took >/= 2 tablets/use day in any 10 use days thus exceeding the label directions during a treatment course.
|
28 days
|
|
Percentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day
Tidsramme: 28 days
|
Percentage of participants who took product with mean daily use >/= 2 tablets /use day thus exceeding the label directions on any use day.
|
28 days
|
|
Percentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken
Tidsramme: 28 days
|
Percentage of participants with at least one dosing occasion where more than one tablet was taken thus exceeding the label directions.
|
28 days
|
|
Percentage of Dosing Occasions Where More Than One Tablet Was Taken
Tidsramme: 28 days
|
Percentage of dosing occasions where more than one tablet was taken thus exceeding the label directions.
|
28 days
|
|
Percentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose
Tidsramme: 28 days
|
Percentage of participants where a dose was taken less than 22 hours after the most recent previous dose thus exceeding the label directions.
22 hrs was chosen to allow for some imprecision in subjects' recollection.
|
28 days
|
|
Percentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose
Tidsramme: 28 days
|
Percentage of dosing occasions where a dose was taken less than 22 hours after the most recent previous dose.
22 hrs was chosen to allow for some imprecision in subjects' recollection
|
28 days
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystemet
- Enzymhemmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Syklooksygenase-hemmere
- Giktdempende midler
- Naproxen
Andre studie-ID-numre
Andre studie-ID-numre
- 15647
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .